Last Price
5.21
Today's Change
-0.01 (0.19%)
Day's Change
5.11 - 5.29
Trading Volume
173,728
Market Cap
1 Billion
Shares Outstanding
271 Million
Avg Volume
1,178,668
Avg Price (50 Days)
3.82
Avg Price (200 Days)
2.36
PE Ratio
-43.42
EPS
-0.12
Earnings Announcement
21-Aug-2024
Previous Close
5.22
Open
5.23
Day's Range
5.11 - 5.29
Year Range
0.675 - 5.67
Trading Volume
173,728
1 Day Change
-0.19%
5 Day Change
0.39%
1 Month Change
32.57%
3 Month Change
97.35%
6 Month Change
215.76%
Ytd Change
148.10%
1 Year Change
561.55%
3 Year Change
247.33%
5 Year Change
247.33%
10 Year Change
247.33%
Max Change
247.33%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.